Acasti Pharma rebrands as Grace Therapeutics; new ticker GRCE effective Oct 28

Grace Therapeutics, Inc.

Company renamed Grace Therapeutics, Inc.; common stock begins trading as GRCE on Nasdaq at market open Oct 28, 2024.
GTx-104 (nimodipine for aSAH) STRIVE-ON trial fully enrolled; data readout expected early 2025, NDA submission H1 2025.
Virtual KOL event on GTx-104 scheduled for Nov 20, 2024 at 2pm ET.
Company completed restructuring, rebuilt management, divested legacy assets, re-domiciled to Delaware.
Addressable U.S. market for GTx-104 estimated at ~$300M; GTx-102 and GTx-101 development deprioritized.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.